Syntal Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Syntal Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,015	Closed	-$1.26M	–	121
2020 Q2	$1.26M	Buy	+2,015	New	+$1.14M	0.59%	57
2019 Q3	–	Sell	-1,000	Closed	-$313K	–	276
2019 Q2	$313K	Hold	1,000	–	–	0.07%	203
2019 Q1	$410K	Hold	1,000	–	–	0.19%	82
2018 Q4	$373K	Hold	1,000	–	–	0.23%	50
2018 Q3	$404K	Hold	1,000	–	–	0.14%	109
2018 Q2	$344K	Hold	1,000	–	–	0.13%	113
2018 Q1	$344K	Hold	1,000	–	–	0.12%	109
2017 Q4	$375K	Buy	+1,000	New	+$405K	0.11%	118

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Syntal Capital Partners's REGN Position: Q3 2020 in Review

Syntal Capital Partners sold out of Regeneron Pharmaceuticals (REGN) in Q3 2020, closing a stake of 2,015 shares — an estimated $1.26M sold.

Syntal Capital Partners first reported a position in REGN in Q4 2017 and held it in 8 quarters. The position peaked at $1.26M in Q2 2020. 907 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

Syntal Capital Partners reported no remaining Regeneron Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Syntal Capital Partners sold 2,015 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $1.26M.
Syntal Capital Partners first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 8 quarters.
Syntal Capital Partners's Regeneron Pharmaceuticals position peaked at $1.26M in Q2 2020.
907 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on Syntal Capital Partners's 13F filing for Q3 2020, filed 26 Oct 2020.